Study guide

7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

Certified Nutrition Support Clinician CNSC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements

1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry

2 Chapter 2: Macronutrients, Micronutrients & Fluid Management

2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements

3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus

3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria

4 Chapter 4: Pediatric & Specialized Nutrition Assessment

4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation

5 Chapter 5: Enteral Nutrition Access & Tube Management

5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care

6 Chapter 6: Enteral Formulation, Regimen Design & Administration

6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements

7 Chapter 7: Enteral Complications & Medication Administration

7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design

8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation

9 Chapter 9: Parenteral Additives, Compounding & Physical Stability

9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration

10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities

10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease

11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support

11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment

12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support

12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure

13 Chapter 13: Oncology, Surgical Care & Intestinal Failure

13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption

14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support

14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education

15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care

15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence

7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

Key Takeaways Explain This Topic AI

Modified-release dosage forms (extended-release, sustained-action, controlled-delivery) must never be crushed for enteral tube administration; crushing destroys the release matrix and precipitates catastrophic 'dose dumping' followed by prolonged subtherapeutic drug levels.

Enteric-coated (EC) formulations must never be crushed, as doing so removes the barrier protecting acid-labile drugs from gastric degradation while exposing the gastric mucosa to direct drug-induced ulceration and irritation.

Liquid oral medications containing sorbitol (often found in commercial elixirs and syrups) act as potent osmotic laxatives; cumulative daily intake exceeding 10 to 20 grams frequently causes severe enteral feeding diarrhea and requires conversion to sorbitol-free dosage forms.

High-impact drug-nutrient interactions require precise timing: phenytoin and levothyroxine require holding enteral feeds 1 to 2 hours before and after administration, while fluoroquinolones (ciprofloxacin) chelate with multivalent cations (Ca²⁺, Mg²⁺, Fe²⁺, Zn²⁺) in formulas, drastically reducing oral bioavailability.

The ASPEN safe medication administration protocol dictates stopping enteral feeds, flushing with 15 to 30 mL water, administering each single medication separately (never co-mingling multiple crushed tablets in a single syringe), flushing with 15 to 30 mL between medications, and delivering a final 15 to 30 mL water flush before resuming feeds.

Last updated: October 2026

7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

Clinical Core: Delivering medications through enteral feeding tubes is fraught with pharmacotherapeutic and mechanical hazards. Altering dosage forms by crushing modified-release or enteric-coated tablets precipitates catastrophic dose dumping, severe toxicity, or drug inactivation. Furthermore, physical chelation, formula protein binding, and vehicle-induced osmotic diarrhea (from excipients like sorbitol) undermine clinical efficacy. Nutrition support clinicians must enforce strict ASPEN medication delivery protocols: flushing between separate medications, honoring drug-holding intervals, and selecting appropriate formulations.

Core Dosage Form Principles: The "Do Not Crush" Rules

Oral solid dosage forms are engineered with specialized chemical coatings, polymeric matrices, and osmotic delivery systems that govern drug dissolution, site-specific absorption, and steady-state kinetics. Crushing a solid dosage form fundamentally alters its pharmacokinetics and can produce lethal consequences. ┌────────────────────────────────────────────────────────┐

  • │ "DO NOT CRUSH" DOSAGE FORMS │
  • └───────────────────────────┬────────────────────────────┘
  • │
  • ┌────────────────────────┬────────┴────────┬────────────────────────┐
  • ▼ ▼ ▼ ▼
  • ┌─────────────────┐ ┌─────────────────┐ ┌────────────────┐ ┌────────────────┐
  • │ Modified-Release│ │ Enteric-Coated │ │ Cytotoxic & │ │ Sublingual / │
  • │ (ER, XR, SR, CD)│ │ (EC) │ │ Hazardous Drugs│ │ Buccal Tablets │
  • ├─────────────────┤ ├─────────────────┤ ├────────────────┤ ├────────────────┤
  • │• Lethal "DOSE │ │• Acid-labile │ │• Aerosolized │ │• Extensive │
  • │ DUMPING" │ │ degradation │ │ hazardous │ │ hepatic first-│
  • │• Acute toxicity │ │• Gastric mucosal│ │ particulates │ │ pass effect │
  • │ followed by │ │ irritation │ │• Risk to staff │ │• Negligible │
  • │ zero efficacy │ │• Severe clumping│ │• Requires CSTD │ │ bioavailabil. │
  • └─────────────────┘ └─────────────────┘ └────────────────┘ └────────────────┘
  • 1. Modified-Release Formulations

Nomenclature: Designated by suffixes including ER / XR (extended-release), XL (extended-length), SR (sustained-release), CR (controlled-release), CD (controlled-delivery), LA (long-acting), TR (time-release), or OROS (osmotic-controlled release oral delivery system).

Mechanism of Danger — Dose Dumping: These formulations contain a full 12- to 24-hour therapeutic payload within a single tablet, engineered to release active drug slowly across the GI tract. Crushing destroys the release-retarding matrix or semi-permeable membrane . The entire 24-hour dose dissolves and absorbs immediately—a phenomenon termed "dose dumping" .

Clinical Outcome: Rapid peak plasma concentrations spike to toxic or fatal levels (e.g., severe hypotension and bradycardia from crushed diltiazem CD or nifedipine XL; fatal respiratory depression from crushed oxycodone CR or morphine ER), followed by a prolonged period of subtherapeutic plasma levels where the patient receives zero therapeutic benefit.

2. Enteric-Coated (EC) Formulations

Mechanism of Action: Formulated with an acid-resistant polymeric coating (e.g., cellulose acetate phthalate) that remains insoluble in the acidic environment of the stomach ( p H < 5.5 pH < 5.5 p H < 5.5 ) but dissolves rapidly in the neutral-to-alkaline duodenum ( p H > 6.0 pH > 6.0 p H > 6.0 ).

Consequences of Crushing:

Acid Inactivation: Acid-labile drugs (e.g., proton pump inhibitors such as omeprazole, pantoprazole) are degraded and inactivated by gastric hydrochloric acid before reaching systemic circulation, rendering therapy useless.

Gastric Mucosal Injury: Medications that are directly corrosive to the stomach lining (e.g., enteric-coated aspirin, potassium chloride, bisacodyl) cause acute chemical gastritis, mucosal erosion, and peptic ulcer bleeding when crushed.

Tube Occlusion: Crushed enteric coatings become sticky and gelatinous upon contact with water or formula, adhering tenaciously to the internal feeding tube lumen and causing intractable clogging.

3. Cytotoxic, Teratogenic, and Hazardous Drugs

Crushing hazardous pharmaceuticals (e.g., antineoplastic chemotherapy agents such as hydroxyurea, methotrexate, tamoxifen, or finasteride) generates airborne aerosolized micro-particles. Inhaling or absorbing these particles exposes nursing staff, pharmacists, and caregivers to significant mutational, teratogenic, and carcinogenic risks. Closed-system drug transfer devices (CSTDs) or liquid commercial formulations must be utilized.

4. Sublingual and Buccal Dosage Forms

Sublingual (e.g., nitroglycerin SL) and buccal formulations are engineered for direct transmucosal absorption into the rich sublingual venous plexus, bypassing the portal vein and avoiding first-pass hepatic metabolism . Swallowing these tablets or instilling them down an enteral feeding tube shunts the drug directly into the portal circulation, where high first-pass hepatic extraction renders the medication clinically inactive.

Liquid Dosage Forms: Osmolality and Sorbitol Hazards

While converting from solid tablets to commercial liquid elixirs, syrups, or suspensions seems intuitive for tube feeding, liquid dosage forms harbor substantial clinical pitfalls.

Hyperosmolality and Dilution

Commercial liquid formulations are typically hypertonic, exhibiting osmolalities between 1,000 and 3,500 mOsm/kg H₂O due to concentrated solubilizing vehicles (sucrose, glycerin, propylene glycol, polyethylene glycol). Instilling an undiluted hyperosmolar elixir directly into the stomach—or worse, directly into the small intestine via a jejunostomy—draws massive volumes of free water into the intestinal lumen, triggering acute abdominal cramping, distension, nausea, and osmotic diarrhea. All liquid medications must be diluted with at least 10 to 30 mL of sterile water prior to enteral tube administration.

The Sorbitol Burden

Sorbitol is an inert, non-absorbable sugar alcohol widely used as a sweetening and stabilizing excipient in liquid elixirs (e.g., liquid acetaminophen, theophylline, furosemide, guaifenesin, and potassium chloride solutions).

Thresholds for Toxicity: Ingesting 5 to 10 grams of sorbitol daily produces abdominal bloating, flatulence, and mild cramping; cumulative daily intakes exceeding 10 to 20 grams provoke severe osmotic diarrhea .

Clinical Rule: In any enterally fed patient who develops unexplained watery diarrhea, calculate the cumulative daily sorbitol load across all prescribed liquid medications. If the total exceeds 10 g/day, consult pharmacy to substitute with crushed immediate-release tablets or intravenous alternatives.

High-Impact Enteral Drug-Nutrient Interactions

Medication Primary Mechanism of Interaction Clinical Management Protocol

Phenytoin (Dilantin) Binds irreversibly to intact formula proteins (calcium caseinate) and adheres to plastic feeding tube walls; serum levels drop by 50% to 70% Hold enteral feeds 1 to 2 hours before and 1 to 2 hours after phenytoin dosing. Flush with 30 mL water before and after. Monitor free (unbound) and total serum phenytoin levels. Adjust oral dose upward or consider IV/fosphenytoin.

Fluoroquinolones (Ciprofloxacin, Levofloxacin) Forms insoluble, non-absorbable chelation complexes with multivalent cations ( C a 2 + , M g 2 + , F e 2 + , A l 3 + , Z n 2 + Ca^{2+}, Mg^{2+}, Fe^{2+}, Al^{3+}, Zn^{2+} C a 2 + , M g 2 + , F e 2 + , A l 3 + , Z n 2 + ) in formula; oral bioavailability falls by 30% to 70% Hold enteral feeds 1 to 2 hours before and after oral dose. Flush thoroughly. Note: Ciprofloxacin is primarily absorbed in the duodenum; jejunal feeding bypasses this site. In severe infections or post-pyloric feeding, convert to intravenous fluoroquinolones .

Warfarin (Coumadin) Enteral formulas contain variable amounts of phylloquinone (vitamin K₁), which directly antagonizes warfarin's inhibition of vitamin K epoxide reductase; formula proteins may also bind warfarin Maintain a consistent, continuous enteral formula infusion rate (avoid erratic starts and stops). Monitor INR every 2 to 3 days when initiating, adjusting, or stopping feeds. Titrate warfarin dose to therapeutic INR while on formula.

Levothyroxine (Synthroid) Adsorbs to dietary fiber, soy protein isolates, and polyvalent cations in enteral formulas, blunting thyroxine intestinal absorption Hold enteral feeds for at least 1 hour before and 1 hour after morning levothyroxine administration. Routinely monitor serum TSH and free T4 levels. Increase oral dose by 25% to 50% if hypothyroid despite holding, or administer IV.

Carbamazepine (Tegretol) High lipophilicity causes carbamazepine suspension to bind to the polyvinyl chloride (PVC) walls of enteral feeding tubes, reducing delivered dose Dilute carbamazepine suspension 1:1 with sterile water prior to administration. Flush tube with 30 mL of water before and after. Monitor serum carbamazepine levels closely. ┌─────────────────────────────────────────────────────────┐

  • │ CATION CHELATION OF FLUOROQUINOLONES │
  • └────────────────────────────┬────────────────────────────┘
  • │
  • ┌────────────────────────────┴────────────────────────────┐
  • ▼ ▼
  • ┌───────────────────────────┐ ┌───────────────────────────┐
  • │ Oral Fluoroquinolone │ │ Multivalent Cations │
  • │ (Ciprofloxacin Molecule) │ │ (Ca²⁺, Mg²⁺, Fe²⁺, Zn²⁺) │
  • └─────────────┬─────────────┘ └─────────────┬─────────────┘
  • │ │
  • └────────────────────────────┬────────────────────────────┘
  • │
  • ▼
  • ┌───────────────────────────────┐
  • │ Insoluble Chelation Complex │
  • │ (Precipitated in Gut Lumen) │
  • ├───────────────────────────────┤
  • │• Molecule becomes unabsorbable│
  • │• Bioavailability drops 30-70% │
  • │• Result: Clinical treatment │
  • │ failure, bacterial resistance│
  • └───────────────────────────────┘
  • The ASPEN Safe Enteral Medication Administration Protocol

To ensure patient safety, prevent physical tube occlusion, avoid chemical drug incompatibilities, and preserve drug bioavailability, the American Society for Parenteral and Enteral Nutrition (ASPEN) has established an evidence-based clinical medication administration protocol. ┌─────────────────────────────────────────┐

  • │ ASPEN ENTERAL MEDICATION PROTOCOL │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ 1. STOP ENTERAL FEEDING │
  • │ (Honor 1-2 hr hold if required) │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ 2. INITIAL FLUSH │
  • │ Flush tube with 15 to 30 mL water │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ 3. ADMINISTER SINGLE MEDICATION │
  • │ • Administer each drug SEPARATELY │
  • │ • NEVER co-mingle drugs in a slurry! │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ 4. INTERMEDIATE FLUSH │
  • │ Flush with 15 to 30 mL water between │
  • │ each individual medication │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ 5. FINAL FLUSH & RESUME │
  • │ • Flush with 15 to 30 mL water │
  • │ • Resume feeds (or honor hold window)│
  • └─────────────────────────────────────────┘
  • Step-by-Step Clinical Procedure

Verify Tube Anatomy & Medication Route: Confirm feeding tube location (gastric vs. duodenal vs. jejunal). Certain medications require gastric acid for dissolution (e.g., ketoconazole, iron salts) and cannot be absorbed efficiently if administered directly into the jejunum.

Temporarily Stop the Feeding Infusion: Pause the enteral pump.

Deliver Initial Flush: Flush the feeding tube with 15 to 30 mL of sterile water to clear all residual formula from the lumen.

Administer Each Medication Separately:

Each solid medication must be finely crushed into a uniform powder and dissolved in 15 to 30 mL of sterile water in its own separate cup.

The Absolute Rule Against Co-Mingling: Clinicians must never crush multiple different tablets together into a single combined syringe or "slurry" . Mixing multiple crushed drugs together creates unpredictable physicochemical incompatibilities, physical precipitates, altered dissolution curves, and extreme tube clogging hazards.

Deliver Intermediate Water Flushes: Flush the tube with 15 to 30 mL of sterile water between each separate medication .

Deliver Final Flush: Flush the tube with 15 to 30 mL of sterile water after administering the final medication.

Resume Enteral Nutrition: Restart the feeding infusion immediately, or observe the mandatory 1- to 2-hour holding window for interacting medications (e.g., phenytoin, ciprofloxacin, levothyroxine).